Faculty of Science and Engineering

School of Engineering, Computing and Mathematics

2020-06-08

# Prevalence of Genes Involved in Colistin Resistance in Acinetobacter baumannii: First Report from Iraq

# Al-Kadmy, IMS

http://hdl.handle.net/10026.1/15265

10.1089/mdr.2019.0243 Microbial Drug Resistance Mary Ann Liebert Inc

All content in PEARL is protected by copyright law. Author manuscripts are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.

Prevalence of genes involved in Colistin Resistance in Acinetobacter baumannii:	1
First report from Iraq	2
Running title: Colistin Resistance in Acinetobacter baumannii	3
	4
Israa M.S. Al-Kadmy <sup>1&amp;2</sup> , Susan A. Ibrahim <sup>2</sup> , Nadal Al-Saryi <sup>2</sup> , Sarah Naji Aziz <sup>2</sup> , Alexander Besinis <sup>1</sup> and Helal F. Hetta <sup>3, 4</sup> .	5 6
<sup>1</sup> Faculty of Science and Engineering, School of Engineering, University of Plymouth, Plymouth, PL4 8AA, <sup>2</sup> Branch of Biotechnology, Department of Biology, College of Science, Mustansiriyah University, POX 102 Baghdad-Iraq	
<sup>3</sup> Department of Medical Microbiology and Immunology, faculty of medicine, Assiut University, Egypt. <sup>4</sup> Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, USA	10 11
	12
*Address correspondence to:	13
Israa M.S. Al-Kadmy	14
Faculty of Science and Engineering, School of Engineering, University of Plymouth, Plymouth, PL4 8AA, UK	15 16
Email: <u>israa.al-kadmy@plymouth.ac.uk</u>	17
ORCID ID: 0000-0002-5109-7338	18
	19
	20
Author contribution:	21
All authors contributed equally to the Literature review, Study plan, Lab work, fund generation, Manuscript writing and proof	22 23
	24
	25
	26
	27
	28
	29

#### Abstract

Background and aim: Colistin is increasingly being used as a 'last-line' therapy to 31 treat infections caused by multi-drug resistant *Acinetobacter baumannii* (*A. baumannii*) 32 isolates, when essentially no other options are available in these days. The aim of this 33 study was to detect genes associated with Colistin resistance in *A. baumannii*. 34

Methods: 121 isolates of A. baumannii were collected from clinical and environmental 35 samples during 2016 to 2018 in Baghdad. Isolates were diagnosed as A. baumannii by 36 using morphological tests, Vitek-2 system, 16SrRNA PCR amplification and 37 sequencing. Antibiotic susceptibility test was carried out using disc diffusion method. 38 Phenotypic detection of colistin resistance was performed by CHROMagar<sup>TM</sup> COL-39 APSE medium and broth microdilution method for the determination of the minimal 40 inhibitory concentration (MIC). Molecular detection of genes responsible for colistin 41 resistance in A. baumannii was performed by PCR. 42

Results: 92 (76%) out of 121 *A. baumannii* isolates were colistin resistant. 26 (21.5%)
out of 121 isolates showed positive growth on CHROM agar *Acinetobacter* base for
MDR. PCR detected *mcr-1*, *mcr-2* and *mcr-3* genes in 89 (73.5%), 78 (64.5%) and 82
(67.8%) in the *A. baumannii* isolates respectively. 78 (64.5%) out of 121 isolates
harbored the integron *intI2* gene and 81 (66.9%) contained *intI3* gene. Moreover, 60
(49.6%) out of 121 isolates were positive for the quorum sensing *Iasl* gene

Conclusion: The presence of a large percentage of colistin resistant A. baumannii49strains in Baghdad may be due to the presence of mobile genetic elements and it is50urgent to avoid unnecessary clinical use of colistin.51

**Keyword**: Colistin, Resistance, *Acinetobacter*, CHROMagar <sup>TM</sup> COL-APSE, pEtN 52 gene, CMS, mobilized colistin resistance. 53

54

55

### **Introduction**

Colistin is a polymyxin E, which possesses cyclic deca-peptide linked to a fatty acyl 56 chain by  $\alpha$ -amide linkage. The only difference in structure between polymyxin E and 57 B is a single amino acid <sup>1</sup>. There are two forms of colistin that are commercially 58 available for use : colistin sulfate and sodium colistin methanesulfonate (CMS)<sup>2</sup>. In the 59

2

1970s, CMS was replaced by aminoglycosides because of the significant side effects of60these antibiotics such as nephrotoxicity and neurotoxicity 3.61

Colistin is an antibiotic that is significantly used against Gram-negative bacteria<sup>4-5</sup>. 62 Due to increased and sometimes-inappropriate use, a rise in colistin resistance was 63 reported <sup>6</sup>. The bacterial cell membrane can be disrupted by ploymyxins, which 64 interfere with phospholipids leading to damage to the osmotic barrier <sup>7</sup>. Polymyxins 65 are ploypeptide molecule with positive charge that act as antimicrobial by disrupting 66 the cell membrane and leading to death of the cell. This disruption occurs as a result of 67 polymyxins binding with negatively charge in lipid A moiety of lipopolysaccharides 68 (LPS)<sup>8</sup>. Resistance to colistin might occur by alteration in binding site in lipid A or 69 efflux pumps <sup>9</sup>. 70

The modification of lipopolysaccharide (LPS) is most prevalent method of 71 resistance, which involves an addition of phosphoethanolamine (PEtN) groups. This is 72 thought to alter the physical properties of the outer membrane, which leads to 73 polymyxin resistance <sup>7</sup>. They are many well-known of PEtN transferases for example 74 EptA from *E. coli*, *H. pylori* and *Vibrio cholerae*. Another example is *PmrC* from *A*. 75 *baumannii*. These enzymes are chromosomally encoded and catalyze the transfer of 76 PEtN from phosphatidylethanolamine (PE) onto the lipid A moiety of LPS<sup>8</sup>. 77

Plasmid-mediated colistin (COL) resistance due to the Mobilized colistin resistance 78 mcr-1 pEtN gene has recently been identified in Asian countries. Bacteria carrying the 79 mcr-1 gene have been isolated from many clinical and environmental sources since it 80 was first described. Moreover, these isolates are often pan-drug resistant (PDR was 81 known as non-susceptibility to all agents in all antimicrobial categories) or extensively 82 drug resistant (XDR was known as non-susceptibility to at least one agent in all but two 83 or fewer antimicrobial categories, bacterial isolates remain susceptible to only one or 84 two categories), which significantly limits the therapeutic options for those organisms 85 <sup>10</sup>. Many studies have identified seven mcr gene families in addition to mcr-1: mcr-2 86 <sup>11</sup>, mcr-3 <sup>12</sup>, mcr-4 <sup>13</sup>, mcr-5 <sup>14</sup>, mcr-6 <sup>15</sup>, mcr-7 <sup>16</sup> and mcr-8 <sup>17</sup>. 87

*Acinetobacter baumannii* (*A. baumannii*) is a multidrug resistant (MDR) bacteria that can spread to civilian hospitals by cross infection of injured military patients repatriated from war zones <sup>18-19</sup>. Two different mechanisms of colistin resistance have been characterized in *A. baumannii* <sup>20-21</sup>. The first mechanism includes complete inactivation of the lipid A biosynthetic pathway and loss of outer membrane LPS. This pathway could be inactivated by deletions, point mutations or insertions in any of three 93 genes  $(lpxA, lpxC, and lpxD)^{22}$ . Consequently, the interaction between LPS and colistin 94 can be prevented leading to increase the MICs of colistin. Colistin resistance due to 95 LPS inactivation has been identified in laboratory mutants and recent clinical isolates 96  $^{23}$ . The second mechanism of colistin resistance is mediated by the PmrAB twocomponent system  $^{24-25}$ . It has been shown that mutations in *pmrB* increased cell 98 sensitivity to colistin more than 100 fold  $^{24}$ . 99

Integrons are genetic elements that allow efficient capture and expression of exogenous100genes that may lead to dissemination of antibiotic resistance, particularly among Gram-101negative bacteria13, 16. Integrons are reported to play a main role in the distribution of102colistin resistance 24-25.103

Antibiotic resistant bacteria communicate through quorum sensing (QS). Quorum 104 sensing system is widely spread in bacteria, which possesses an important role in 105 controlling virulence factors. Therefore, it is considered as a "speaking" system in 106 bacterium <sup>26</sup>. QS is a way bacteria secret chemical signals called auto-inducers to 107 communicates with each other and is often followed by alteration in expression in 108 genes expression <sup>3, 10, 16</sup>. The persistent modification of bacterial species or strains is a 109 global issue. Both gram-positive and gram-negative bacteria uses inducer called 110 acylated homoserine lactones (AHLs) as a chemical signal or auto chemo-inducer. 111 Although the mechanisms of signaling are different from species to species <sup>3, 10, 16</sup>, OS-112 controlled gene expression plays a major role in the antibiotic resistant in pathogens. 113

The aim of this study was to detect genes, which might be associated with colistin 114 resistance in *A. baumannii*. As a result of the increasing distribution of serious 115 infections with gram negative bacteria, colistin is increasingly being used as therapy to 116 treat infections caused by MDR *A. baumannii* because there is a lack of other options. 117

118

119

120

#### Material and Methods

This work was done as a collaboration between Mustansiriyah University, Iraq, Assiut121University, Egypt and University of Cincinnati medical center, USA.122In this study, 121 isolates of A. baumannii were collected from clinical (30 isolates123from urine samples, 47 isolates from blood, 31 isolates from wound swabs, 4 isolates124124125

8 isolates from soil) samples from different hospitals across Baghdad during 2016 -	126
2018.	127
Detection of A. baumannii:	128
The phenotypic characterization was performed using morphological tests,	129
CHROMagar Acinetobacter, and Vitek-2 system (BioMérieux, France).	130
Conventional PCR was performed for the genotypic identification of A. baumannii	131
species using specific primers for 16SrRNA gene as previously described. <sup>27</sup>	132
The sequence of the primers and PCR cycling conditions are listed in Table (1).	133
	134

#### Phenotypic detection of colistin resistance in A. baumannii:

We used CHROMagar<sup>TM</sup> COL-APSE (Paris, France) media for detection of colistin 136 resistance and broth microdilution method for the determination of minimal inhibitory 137 concentrations (MIC). Broth microdilution is recommended by CLSI for testing colistin 138 susceptibility. Strains which showed colistin MIC values >2  $\mu$ g/mL were interpreted as 139 resistant according to CLSI, 2016 breakpoints <sup>(24)</sup>, and using quality controlled standard 140 strains (*Acinetobacter baumanii ATCC BAA-747*) obtained from American Type 141 Culture Collection. 142

#### Phenotypic detection of MDR in A. baumannii

Then used CHROMagar Acinetobacter Base with supplement (S) and MDR 145 Supplement for detection on MDR isolates (MDR: resistance to C3G, quinolones, 146 carbapenem etc). We prepared CHROMagar<sup>TM</sup> COL-APSE plates using dehydrated 147 CHROMagar<sup>TM</sup> base media (X207B) with the CHROMagar<sup>TM</sup> COL-APSE supplement 148 (X207S) + CHROMagar<sup>TM</sup> Anti-swarming supplement (X208). These mediums were 149 not autoclaved in order preserve the CHROMogenic compounds included in the 150 mixture and instead were sterilized by boiling at 100°C while swirling or stirring 151 regularly, prior to the addition of the supplements. 152

153

135

143

144

The antibiotic susceptibility profile for *A. baumannii* isolates was determined 154 using Kirby-Bauer disc diffusion test and interpreted as recommended by Clinical 155 Laboratory Standards Institute <sup>(24)</sup>. Susceptibility testing was performed by inoculating 156 Mueller-Hinton agar plates (Thermo Fisher Scientific and Waltham, MA, USA) used 157 the suspension equivalent in turbidity to 0.5 McFarland. Then, we incubated the plates 158 overnight at 37°C before recording the results. 159

	160
The following commonly used antibiotics were tested: ampicillin, amoxycillin,	161
aztreonam, cefepime, cefotaxime, cefoperazone, ceftazidime, imipenem, meropenem,	162
clindamycin, colistin, gentamicin, amikacin, tetracycline, chloramphenicol,	163
ciprofloxacin, amoxycillin/clavulanic acid and trimethoprime/sulphamethoxazole.	164
	165
Molecular detection of Colistin resistance genes:	166
The entire genomic DNA extraction was performed for all resistance isolates	167
according to modified Microwave lysis method <sup>25</sup> .	168
Colistin resistance genes <i>mcr-1</i> , <i>mcr-2</i> and <i>mcr-3</i> were detected by PCR for all isolates	169
grown on CHROMagar <sup>TM</sup> COL-APSE.	105
The primer sequences and the amplicon size of different genes are listed in Table (1).	170
Briefly, the PCR reaction mixture consisted of 12.5 µl of 2X GoTaq®Green Master	172
Mix (KAPA, South Africa), 3 µl template DNA, 2 µl primers for each forward and	173
reverse primers with final concentration (0.6 pmol/ $\mu$ l), and complete the volume to 25	174
$\mu$ with nuclease free water. The amplified PCR product was run in agarose gel	175
electrophoresis and compared with 100 bp DNA ladder (KAPA, South Africa) and then	176
visualized under UV trans-illuminator.	177
	178
Detection of integrons on colistin resistant A. baumannii:	179
PCR was used to detect <i>intI2</i> and <i>intI3</i> genes, which represent the class 2 and class 3	180
integrons that are known to be associated with MDR <i>A. baumannii</i> . The primer	181
sequences and the amplicon size of genes are listed in Table (1).	182
sequences and me ampreon size of genes are insee in Table (1).	183
Detection of quorum sensing in colistin resistant A. baumannii:	184
The presences of <i>Iasl</i> gene, as a part of the QS system, was investigated by PCR in A.	185
<i>baumannii</i> isolates. The primer sequences and the amplicon size of different genes are	186
listed in Table (1).	187
<u>Results and Discussion</u>	188
Kojunoj and Discussion	100
-Phenotypic properties	189
121 isolates of A. baumannii were collected from different samples during 2016 to	190
2018 in Baghdad. 16SrRNA PCR amplification and sequencing were used to identify	191

A. baumannii isolates. A. baumannii is gram negative, can cause many infections due
to its multi-drug resistance <sup>(18, 20, 25)</sup>.
193

26 (21.5%) out of 121 isolates showed positive growth with red colonies on CHROM agaff94 *Acinetobacter* base for MDR suggesting the isolates were resistant to C3G, quinolones and195 carbapenem (CHROMagarTM *Acinetobacter*, 2018). The source of these 26 MDR isolates196 was environmental sample (n=1), from urinary tract infections (n=2), blood (n=12), wound 197 swabs (n=6), cerebrospinal fluid (n=4) and endotracheal tube (n=1) 198

#### - Resistance of Acinetobacter:

The ability of the isolates to resist colistin was investigated by using CHROMagar<sup>TM</sup> 200 COL-APSE (Paris, France) medium and confirmed by broth microdilution for 201 determination of MIC. Isolates were detected by cream colonies on this medium 202 (CHROMagar<sup>™</sup> COL-APSE, 2018). The results showed that 92(76.03%) isolates 203 (including one environmental isolate) showed positive growth on the CHROMagar<sup>TM</sup> 204 COL-APSE medium. In addition, the MIC for these isolate was measured using broth 205 microdilution for determination of MIC. The isolates showed MIC value ranged from 206 4 to 16 g/ml. 207

Antibiotic susceptibility pattern of *A. baumannii* isolated from clinical and 208 environmental samples for different classes of antibiotics showed in Table (2). The 209 result showed that the isolates were 100% resistant to  $\beta$ -lactum and Cefotaxime 210 antibiotics, while they were less resistant (30%) to Tetracycline. PCR were performed 211 to investigate the *mcr* related genes and their role in the resistance of *A. baumannii* 212

The mcr-1 gene was detected in 89 (73.6%) isolates; the mcr-2 gene detected in 78213(64.5%) and the mcr-3 gene was detected in 82 (67.7%) in the A. baumannii (Table 3).214

215

199

CHROMagar COL-APSE medium was able to support the growth of colistin 216 resistant Gram-negative bacteria because it is a sensitive and specific media for the 217 growth of colistin resistant bacterial pathogens with a lower limit of detection of  $10^{1}$ 218 CFU <sup>26</sup>. Resistance to antibiotic is a global issue. The limitation of effective treatment 219 carbapenem treatment is leading to reduce treatment options for multidrug resistant 220 bacteria <sup>28-34</sup>. The (mobilized colistin resistance) mcr-1 gene has been reported in 221 Escherichia coli and Klebsella pneumoniae from China, which encodes 222 phosphoethanolamine transferase<sup>10</sup>. It has the ability to be transferred between different 223

bacterial strains. This leads to antibiotic resistance because of alterations in the bacterial 224 cell membrane lipid A  $^{10, 23, 35}$ . Gene *mcr-2* has been reported in 76% of bacteria with 225 *mcr-1* gene from Belgium  $^{11}$ . In addition, *mcr-3* gene has been recently reported in *E*. 226 *coli* of pig origin, which showed a 45.0% and 47.0% identity in nucleotide sequence to 227 *mcr-1* and *mcr-2*, respectively  $^{12}$ . 228

Results highlighted the rapid spreading of mcr-1, mcr-2 and mcr-3 genes globally. 229 Recently, mcr-1 has been isolated from *Enterobacteriaceae* (animals), products of 230 animals, humans and environments in more than thirty different countries from five 231 continents <sup>36</sup>. This rapid increase in the reporting of resistance mechanism in a short 232 time is alarming. 233

234

235

254

#### - Role of integrons on MDR distribution

PCR was used to detect the class 2 and class 3 integrons in isolates of Acinetobacter236baumannii, which associated with multi-drugs resistances. The results showed out of237121 isolates, 78 (64.5%) harbored *intI2* gene and 81 (66.9%) contained *intI3* gene238(Table 3). These results confirmed the role of integrons in MDS distribution in A.239baumannii, which is similar to the role of integrons in the distribution of MDR in240Salmonella spp. in Rajaei, et al. <sup>37</sup>.241

Integron genes play a key role in the horizontal transfer of antibiotic multi-242 resistance companying with genetic element. Resistance genes are either on the host 243 plasmid or bacterial chromosome  $^{13, 38-39}$ . The *intI* gene encodes for an integrase, which 244 belongs to the tyrosine-recombinase family <sup>40</sup>. The activity of integrase includes 245 recombination of separate DNA molecules as gene cassettes. Integrons are divided 246 into two subsets: the mobile integrons that are responsible for spreading the anti-drug 247 resistance genes and super integrons. According to sequencing, there are five classes of 248 integrons 41-42. 249

Integrons have the ability to capture the antibiotic resistance cassettes genes that 250 lead to distribution of MDR and decrease the infection treatment options <sup>43</sup>. Resistance 251 cassettes have been reported in both gram negative bacteria and gram positive bacteria 252 44-46. 253

#### - Quorum sensing detection in Acinetobacter

This system was first discovered in 1994 by Dr. Peter Greenberg in Vibrio255fischeri. The QS system is a chemical mediated cell-to-cell communication that can256regulate gene expression and the activity of the group in communities 47. There are257

many activities depending on the QS system such as production, secretion, and 258 detection of small signaling molecules named Autoinducers (AIs)<sup>48</sup>. 259

The presences of *Iasl* gene in *Acinetobacter* isolates were investigated by PCR. 260 The results indicated that 60 (49.6 %) out of 121 isolates were positive for *Iasl* gene 261 (Table 3). Bacteria use QS to regulate genes expression, facilitate pathogenic invasion 262 and spread virulence factors <sup>49</sup>. The QS controls local bacteria population and cell 263 density, which make the bacteria behave as a collaborative community such as 264 multicellular organism<sup>50</sup>. Bacterial QS regulates bioluminescence, competence, 265 antibiotic production and secretion of virulence factors <sup>51</sup>. This affects the formation of 266 biofilm <sup>52-53</sup>, drug sensitivity <sup>54</sup> and bacterial virulence <sup>55</sup>. 267

The *lasI* gene is as a part of QS system, the product of this gene being N-(3-oxododecanoyl) -L- homoserine lactone (3-oxo-C12-AHL), which interacts with *LasR* and activates target promoters <sup>56</sup>. Only the multimeric form of this protein is active and can bind to target DNA and regulate the transcription of multiple genes at high cell densities <sup>57</sup>.

#### **Conclusion**

MDR A. baumannii is considered to be a serious threat. The current study showed that 274 there is a high prevalence of colistin resistance in A. baumannii strains isolated from 275 Iraq. This is associated with the ability of this pathogen to acquire new genetic material 276 leading to increase the resistance. In addition, integrons showed a major role in 277 extending the bacterial ability to grow in different challenge conditions because it 278 allows A. baumannii to capture additional genetic material from other species. This 279 leads to the distribution and increased the resistance of A. baumannii. This resistance 280 can transform in over the world by natural transformation. The presence of a large 281 percentage of colistin resistant A. baumannii strains in Baghdad makes it urgent to avoid 282 unnecessary clinical use of colistin. 283

284

273

285

286

287

## Acknowledgement

The authors would like to thank Mustansiriyah University 288 (<u>https://uomustansiriyah.edu.iq/)</u> / Baghdad, Iraq for its support to complete this work. In 289

addition, we would like to thank Mr. Gwladys Chansigaud and R&D Department CHROMagar	290
(www.CHROMagar.com) in Paris to support us all CHROM agar media.	291
	292
Disclosure Statement: No competing financial interests exist.	293
	294

<u>References:</u>	295
1. Storm, D. R.; Rosenthal, K. S.; Swanson, P. E., Polymyxin and related peptide antibiotics. Annual review of biochemistry <b>1977</b> , 46 (1), 723-763.	296 297
2. Bergen, P. J.; Li, J.; Rayner, C. R.; Nation, R. L., Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa. <i>Antimicrobial agents and chemotherapy</i> <b>2006</b> , <i>50</i> (6), 1953-1958.	298 299 300
3. Li, J.; Nation, R. L.; Turnidge, J. D.; Milne, R. W.; Coulthard, K.; Rayner, C. R.; Paterson, D. L., Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. <i>The Lancet infectious diseases</i> <b>2006</b> , <i>6</i> (9), 589-601.	301 302 303
4. Nation, R. L.; Li, J., Colistin in the 21st century. <i>Current opinion in infectious diseases</i> <b>2009,</b> <i>22</i> (6), 535.	304 305
5. El-Mokhtar, M. A.; Mandour, S. A.; Shahat, A. A., Colistin resistance among multidrug- resistant E. coli isolated from	306 307
Upper Egypt. Egyptian Journal of Medical Microbiology 2019, 28 (2), 11-17.	308
6. Ko, K. S.; Suh, J. Y.; Kwon, K. T.; Jung, SI.; Park, KH.; Kang, C. I.; Chung, D. R.; Peck, K. R.; Song, JH., High rates of resistance to colistin and polymyxin B in subgroups of Acinetobacter baumannii isolates from Korea. <i>Journal of Antimicrobial Chemotherapy</i> <b>2007</b> , <i>60</i> (5), 1163-1167.	309 310 311 312
7. Hawley, J. S.; Murray, C. K.; Jorgensen, J. H., Development of colistin-dependent Acinetobacter baumannii-Acinetobacter calcoaceticus complex. <i>Antimicrobial agents and chemotherapy</i> <b>2007</b> , <i>51</i> (12), 4529-4530.	313 314 315
8. Yahav, D.; Farbman, L.; Leibovici, L.; Paul, M., Colistin: new lessons on an old antibiotic. Clinical microbiology and infection <b>2012,</b> 18 (1), 18-29.	316 317
9. Tzeng, YL.; Ambrose, K. D.; Zughaier, S.; Zhou, X.; Miller, Y. K.; Shafer, W. M.; Stephens, D. S., Cationic antimicrobial peptide resistance in Neisseria meningitidis. <i>Journal of bacteriology</i> <b>2005</b> , <i>187</i> (15), 5387-5396.	318 319 320
10. Liu, YY.; Wang, Y.; Walsh, T. R.; Yi, LX.; Zhang, R.; Spencer, J.; Doi, Y.; Tian, G.; Dong, B.; Huang, X., Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. <i>The Lancet infectious diseases</i> <b>2016</b> , <i>16</i> (2), 161-168.	321 322 323 324
11. Xavier, B. B.; Lammens, C.; Ruhal, R.; Kumar-Singh, S.; Butaye, P.; Goossens, H.; Malhotra- Kumar, S., Identification of a novel plasmid-mediated colistin-resistance gene, mcr-2, in Escherichia coli, Belgium, June 2016. <i>EuroSurveillance Monthly</i> <b>2016</b> , <i>21</i> (27), 30280.	325 326 327
12. Yin, W.; Li, H.; Shen, Y.; Liu, Z.; Wang, S.; Shen, Z.; Zhang, R.; Walsh, T. R.; Shen, J.; Wang, Y., Novel plasmid-mediated colistin resistance gene mcr-3 in Escherichia coli. <i>MBio</i> <b>2017</b> , <i>8</i> (3), e00543-17.	328 329 330
13. Carattoli, A., Importance of integrons in the diffusion of resistance. <i>Veterinary research</i> <b>2001</b> , <i>32</i> (3-4), 243-259.	331 332
14. Borowiak, M.; Fischer, J.; Hammerl, J. A.; Hendriksen, R. S.; Szabo, I.; Malorny, B., Identification of a novel transposon- 3345sociated phosphoethanolamine transferase 11	333

gene, mcr-5, conferring colistin resistance in d-tartrate fermenting Salmonella enterica subsp.335enterica serovar Paratyphi B. Journal of Antimicrobial Chemotherapy 2017, 72 (12), 3317-3363324.337

Partridge, S. R.; Di Pilato, V.; Doi, Y.; Feldgarden, M.; Haft, D. H.; Klimke, W.; Kumar-Singh,
 S.; Liu, J.-H.; Malhotra-Kumar, S.; Prasad, A., Proposal for assignment of allele numbers for
 mobile colistin resistance (mcr) genes. *Journal of Antimicrobial Chemotherapy* 2018, 73 (10),
 2625-2630.

16. Wang, X.; Wang, Y.; Zhou, Y.; Li, J.; Yin, W.; Wang, S.; Zhang, S.; Shen, J.; Shen, Z.; Wang,342Y., Emergence of a novel mobile colistin resistance gene, mcr-8, in NDM-producing Klebsiella343pneumoniae. Emerging microbes & infections 2018, 7 (1), 122.344

Litrup, E.; Kiil, K.; Hammerum, A. M.; Roer, L.; Nielsen, E. M.; Torpdahl, M., Plasmid-borne
 colistin resistance gene mcr-3 in Salmonella isolates from human infections, Denmark, 2009–
 *Eurosurveillance* 2017, *22* (31).

18. Peleg, A. Y.; Seifert, H.; Paterson, D. L., Acinetobacter baumannii: emergence of a 348 successful pathogen. *Clinical microbiology reviews* **2008**, *21* (3), 538-582. 349

19. Kareem, S. M.; Al-Kadmy, I. M.; Al-Kaabi, M. H.; Aziz, S. N.; Ahmad, M., Acinetobacter350baumannii virulence is enhanced by the combined presence of virulence factors genes351phospholipase C (plcN) and elastase (lasB). *Microbial pathogenesis* 2017, 110, 568-572.352

20. Cai, Y.; Chai, D.; Wang, R.; Liang, B.; Bai, N., Colistin resistance of Acinetobacter baumannii:353clinical reports, mechanisms and antimicrobial strategies. Journal of antimicrobial354chemotherapy 2012, 67 (7), 1607-1615.355

21. AL-Kadmy, I. M.; Ali, A. N. M.; Salman, I. M. A.; Khazaal, S. S., Molecular characterization356of Acinetobacter baumannii isolated from Iraqi hospital environment. New microbes and new357infections 2018, 21, 51-57.358

22. Henry, R.; Vithanage, N.; Harrison, P.; Seemann, T.; Coutts, S.; Moffatt, J. H.; Nation, R. L.;
25. Li, J.; Harper, M.; Adler, B., Colistin-resistant, lipopolysaccharide-deficient Acinetobacter
26. baumannii responds to lipopolysaccharide loss through increased expression of genes
27. Harper, M.; Adler, B., Colistin-resistant, lipopolysaccharide-deficient Acinetobacter
28. Baumannii responds to lipopolysaccharide loss through increased expression of genes
29. Baumannii responds to lipopolysaccharide loss through increased expression of genes
20. Baumannii responds to lipopolysaccharide loss through increased expression of genes
29. Baumannii responds to lipopolysaccharide loss through increased expression of genes
20. Baumannii responds to lipopolysaccharide loss through increased expression of genes
20. Baumannii responds to lipopolysaccharide loss through increased expression of genes
20. Baumannii responds to lipopolysaccharide loss through increased expression of genes
20. Baumannii responds to lipopolysaccharide loss through increased expression of genes
20. Baumannii responds to lipopolysaccharide loss through increased expression of genes
20. Baumannii responds to lipopolysaccharide loss through increased expression of genes
20. Baumannii responds to lipopolysaccharide loss through increased expression of genes
20. Baumannii responds to lipopolysaccharide loss through increased expression of genes
20. Baumannii responds to lipopolysaccharide loss through increased expression of genes
20. Baumannii responds to lipopolysaccharide loss through increased expression of genes
20. Baumannii responds to lipopolysaccharide loss through increased expression of genes
20. Baumannii responds to lipopolysaccharide loss through increased expression of genes
20. Baumannii responds to lipopolysaccharide loss through increased expr

23. Moffatt, J. H.; Harper, M.; Harrison, P.; Hale, J. D.; Vinogradov, E.; Seemann, T.; Henry, R.;
364
Crane, B.; Michael, F. S.; Cox, A. D., Colistin resistance in Acinetobacter baumannii is mediated
by complete loss of lipopolysaccharide production. *Antimicrobial agents and chemotherapy*366
2010, 54 (12), 4971-4977.

24. CLSI. (2016). Performance standard for antimicrobial susceptibility testing; Twenty-First368informational supplement. M100-S26.vol.36 No.(1).369

25. Adams, M. D.; Nickel, G. C.; Bajaksouzian, S.; Lavender, H.; Murthy, A. R.; Jacobs, M. R.;
Bonomo, R. A., Resistance to colistin in Acinetobacter baumannii associated with mutations
in the PmrAB two-component system. *Antimicrobial agents and chemotherapy* 2009, *53* (9),
3628-3634.

26. Yin, W.-F.; Purmal, K.; Chin, S.; Chan, X.-Y.; Koh, C.-L.; Sam, C.-K.; Chan, K.-G., N-acyl374homoserine lactone production by Klebsiella pneumoniae isolated from human tongue375surface. Sensors 2012, 12 (3), 3472-3483.376

27. Hasen Esaa, R.; N N Naji, E.; Sami, H., Comparison of three diagnostic methods for 377 Acinetobacter baumannii Isolated from Baghdad Hospitals. 2016. 378 28. Balaji, V.; Jeremiah, S.; Baliga, P., Polymyxins: antimicrobial susceptibility concerns and 379 therapeutic options. Indian journal of medical microbiology **2011**, 29 (3), 230. 380 29. Farhan, S. M.; Ibrahim, R. A.; Hetta, H. F.; Mahran, K. M.; Abdelbaky, R. M., PREVALENCE 381 OF OXA-23 IN MULTIDRUG RESISTANCE ACINETOBACTER BAUMANNII ISOLATED FROM 382 DIFFERENT INFECTIONS AT MINIA UNIVERSITY HOSPITAL. 2018. 383 30. El-Mokhtar, M. A.; Hetta, H. F., Ambulance vehicles as a source of multidrug-resistant 384 infections: a multicenter study in Assiut City, Egypt. Infection and drug resistance 2018, 11, 385 587. 386 31. Ahmed, S.; Ahmed, S.; Mohamed, W.; Feky, M.; Daef, E.; Badary, M.; Hetta, H., Nosocomial 387 vancomycin and methicillin resistant staphylococcal infections in intensive care units in Assiut 388 University Hospitals. *Egyptian Journal of Medical Microbiology* **2011**, *20* (2). 389 32. Farhan, S. M.; Ibrahim, R. A.; Mahran, K. M.; Hetta, H. F.; El-Baky, R. M. A., Antimicrobial 390 resistance pattern and molecular genetic distribution of metallo- $\beta$ -lactamases producing 391 Pseudomonas aeruginosa isolated from hospitals in Minia, Egypt. Infection and Drug 392 *Resistance* **2019,** *12*, 2125. 393 33. El-Baky, R. M. A.; Sandle, T.; John, J.; Abuo-Rahma, G. E.-D. A.; Hetta, H. F., A novel 394 mechanism of action of ketoconazole: inhibition of the NorA efflux pump system and biofilm 395 formation in multidrug-resistant Staphylococcus aureus. Infection and drug resistance 2019, 396 *12*, 1703. 397 34. Al-Saryi, N.; Ibrahim, S. A.; AL-Kadmy, I. M.; Hetta, H. F., Whole genome sequencing of 398 Streptococcus pneumoniae serotype 33C causing fatal sepsis in a hospitalized patient with 399 nephrotic syndrome. Gene Reports 2019, 100434. 400 35. Hinchliffe, P.; Yang, Q. E.; Portal, E.; Young, T.; Li, H.; Tooke, C. L.; Carvalho, M. J.; Paterson, 401 N. G.; Brem, J.; Niumsup, P. R., Insights into the mechanistic basis of plasmid-mediated colistin 402 resistance from crystal structures of the catalytic domain of MCR-1. Scientific reports 2017, 7, 403 39392. 404 405 36. Wang, Y.; Tian, G.-B.; Zhang, R.; Shen, Y.; Tyrrell, J. M.; Huang, X.; Zhou, H.; Lei, L.; Li, H.-406 Y.; Doi, Y., Prevalence, risk factors, outcomes, and molecular epidemiology of mcr-1-positive Enterobacteriaceae in patients and healthy adults from China: an epidemiological and clinical 407 study. *The Lancet Infectious Diseases* **2017**, *17* (4), 390-399. 408 37. Rajaei, B.; Siadat, S. D.; Razavi, M. R.; Aghasadeghi, M. R.; Rad, N. S.; Badmasti, F.; Jafroodi, 409 S. K.; Rajaei, T.; Moshiri, A.; Javadian, S., Expanding drug resistance through integron 410 acquisition in Salmonella spp. isolates obtained in Iran. African Journal of Microbiology 411 *Research* **2011**, *5* (16), 2249-2253. 412 38. Tamang, M. D.; Oh, J. Y.; Seol, S. Y.; Kang, H. Y.; Lee, J. C.; Lee, Y. C.; Cho, D. T.; Kim, J., 413 Emergence of multidrug-resistant Salmonella enterica serovar Typhi associated with a class 1 414 integron carrying the dfrA7 gene cassette in Nepal. International journal of antimicrobial 415 agents 2007, 30 (4), 330-335. 416

39. Yang, B.; Zheng, J.; Brown, E. W.; Zhao, S.; Meng, J., Characterisation of antimicrobial resistance-associated integrons and mismatch repair gene mutations in Salmonella serotypes. <i>International journal of antimicrobial agents</i> <b>2009</b> , <i>33</i> (2), 120-124.	417 418 419
40. Hall, R. M.; Collis, C. M., Mobile gene cassettes and integrons: capture and spread of genes by site-specific recombination. <i>Molecular microbiology</i> <b>1995</b> , <i>15</i> (4), 593-600.	420 421
41. Hall, R. M. In <i>Mobile gene cassettes and integrons: moving antibiotic resistance genes in gram-negative bacteria</i> , Ciba Foundation Symposium 207-Antibiotic Resistance: Origins, Evolution, Selection and Spread: Antibiotic Resistance: Origins, Evolution, Selection and Spread: Ciba Foundation Symposium 207, Wiley Online Library: 2007; pp 192-205.	422 423 424 425
42. Mazel, D., Integrons: agents of bacterial evolution. <i>Nature Reviews Microbiology</i> <b>2006</b> , <i>4</i> (8), 608.	426 427
43. Stokes, H. t.; Hall, R. M., A novel family of potentially mobile DNA elements encoding site-specific gene-integration functions: integrons. <i>Molecular microbiology</i> <b>1989</b> , <i>3</i> (12), 1669-1683.	428 429 430
44. Nešvera, J.; Hochmannová, J.; Pátek, M., An integron of class 1 is present on the plasmid pCG4 from gram-positive bacterium Corynebacterium glutamicum. <i>FEMS microbiology letters</i> <b>1998,</b> <i>169</i> (2), 391-395.	431 432 433
45. Nandi, S.; Maurer, J. J.; Hofacre, C.; Summers, A. O., Gram-positive bacteria are a major reservoir of Class 1 antibiotic resistance integrons in poultry litter. <i>Proceedings of the National Academy of Sciences</i> <b>2004</b> , <i>101</i> (18), 7118-7122.	434 435 436
46. Tauch, A.; Götker, S.; Pühler, A.; Kalinowski, J.; Thierbach, G., The 27.8-kb R-plasmid pTET3 from Corynebacterium glutamicum encodes the aminoglycoside adenyltransferase gene cassette aadA9 and the regulated tetracycline efflux system Tet 33 flanked by active copies of the widespread insertion sequence IS6100. <i>Plasmid</i> <b>2002</b> , <i>48</i> (2), 117-129.	437 438 439 440
47. Yang, L.; Tolker-Nielsen, T.; Molin, S. Pseudomonas aeruginosa quorum-sensing-A factor in biofilm development, and an antipathogenic drug target. Technical University of Denmark (DTU), 2009.	441 442 443
48. Kalia, V. C.; Purohit, H. J., Quenching the quorum sensing system: potential antibacterial drug targets. <i>Critical reviews in microbiology</i> <b>2011,</b> <i>37</i> (2), 121-140.	444 445
49. Bose, S.; Ghosh, A. K., Understanding of quorum–sensing: a possible solution for drug resistance in bacteria. <i>Int J Curr Microbiol App Sci</i> <b>2016,</b> <i>5</i> (2), 540-546.	446 447
50. LaSarre, B.; Federle, M. J., Exploiting quorum sensing to confuse bacterial pathogens. <i>Microbiology and molecular biology reviews</i> <b>2013,</b> <i>77</i> (1), 73-111.	448 449
51. Labbate, M.; Queck, S. Y.; Koh, K. S.; Rice, S. A.; Givskov, M.; Kjelleberg, S., Quorum sensing-controlled biofilm development in Serratia liquefaciens MG1. <i>Journal of bacteriology</i> <b>2004</b> , <i>186</i> (3), 692-698.	450 451 452
52. Cady, N. C.; McKean, K. A.; Behnke, J.; Kubec, R.; Mosier, A. P.; Kasper, S. H.; Burz, D. S.; Musah, R. A., Inhibition of biofilm formation, quorum sensing and infection in Pseudomonas aeruginosa by natural products-inspired organosulfur compounds. <i>PLoS One</i> <b>2012</b> , <i>7</i> (6), e38492.	453 454 455 456

53. Jakobsen, T. H.; Bragason, S. K.; Phipps, R. K.; Christensen, L. D.; van Gennip, M.; Alhede M.; Skindersoe, M.; Larsen, T. O.; Høiby, N.; Bjarnsholt, T., Food as a source for quorum sensing inhibitors: iberin from horseradish revealed as a quorum sensing inhibitor of Pseudomona aeruginosa. <i>Appl. Environ. Microbiol.</i> <b>2012</b> , <i>78</i> (7), 2410-2421.	g 458
54. Brackman, G.; Cos, P.; Maes, L.; Nelis, H. J.; Coenye, T., Quorum sensing inhibitors increase the susceptibility of bacterial biofilms to antibiotics in vitro and in vivo. <i>Antimicrobial agent</i> and chemotherapy <b>2011</b> , <i>55</i> (6), 2655-2661.	
55. Koh, K. H.; Tham, FY., Screening of traditional Chinese medicinal plants for quorum sensing inhibitors activity. <i>Journal of Microbiology, Immunology and Infection</i> <b>2011</b> , <i>44</i> (2) 144-148.	
56. Smith, R. S.; Iglewski, B. H., Pseudomonas aeruginosa quorum sensing as a potentia antimicrobial target. <i>Journal of Clinical Investigation</i> <b>2003</b> , <i>112</i> (10), 1460.	l 467 468
57. Siehnel, R.; Traxler, B.; An, D. D.; Parsek, M. R.; Schaefer, A. L.; Singh, P. K., A unique regulator controls the activation threshold of quorum-regulated genes in Pseudomona aeruginosa. <i>Proceedings of the National Academy of Sciences</i> <b>2010</b> , <i>107</i> (17), 7916-7921.	
	472
	473

Gene	Sequence	<b>TM</b> (°C)	Products size (bp)
16srRNA	5'-TTTAAGCGAGGAGGAGG-3' 5'-ATTCTACCATCCTCTCCC-3'	58	240
mcr-1	5'-CACTTATGGCACGGTCTATGA-3' 5'-CCCAAACCAATGATACGCAT-3'	59	956
mcr-2	5'-:TGGTACAGCCCCTTTATT-3' 5'-GCTTGAGATTGGGTTATGA-3'	57	1,617
mcr-3	5-TTGGCACTGTATTTTGCATTT-3 5-TTAACGAAATTGGCTGGAACA-3	50	542
intI2	5'-CAC GGA TAT GCGACA AAA AGG-3' 5'-TGTA GCA AAC GAGTGA CGA AAT G-3'	60	788
intI3	5'-AGT GGG TGG CGAATG AGT G-3' 5'-TGT TCT TGT ATCGGC AGG TG-3'	60	600
lasI	5'- TCGACGAGATGGAAATCGATG-3' 5'- GCTCGATGCCGATCTTCAG-3'	59	402

**Table 1:** The PCR primers used and the amplicon size of different genes involved in this study47427475

Class of antibiotics	Antibiotic tested	<b>Resistant strains for 121</b> of <i>A. baumannii</i> isolates
penicillins	Ampicillin	% 100
	Amoxycillin	% 100
Monobactam	Aztereonam	%90
3rd generation cephalosporin	Cefotaxime	% 100
	Cefoperazone	%85.9
	Ceftazidine	%93
4 <sup>th</sup> generation cephalosporin	Cefepime	%96
Carbapenemes	Imipenem	%44.7
-	Meropenem	%36
Polypeptide	Clindamycin	%91.6
	Colistin	%76
Aminoglycosides	Gentamicin	%79
	Amikacin	%72
Tetracyclines	Tetracycline	%30
Amphenicols	Chloramphenicol	%72
quinolones	Ciprofloxacin	%79
Combination	Amoxycillin/clavulanicacid	%96
	Trimethoprime/sulphametoxazole	%91.6

PCR test	Positive result (%)	Negative result
mcr-1	89 (73.6%)	32 (26.4%)
mcr-2	78 (64.5%)	43 (35.5%)
mcr-3	82 (67.7%)	39 (32.2%)
mcr-1+ mcr-2	74(61.1%)	47(38.8%)
<i>mcr-1</i> + <i>mcr-3</i>	77(63.6%)	44(36.3%)
<i>mcr-2+ mcr-3</i>	69(57.02%)	52(42.9%)
<i>mcr-1</i> + <i>mcr-2</i> + <i>mcr-3</i>	66(54.5%)	55(45.4%)
intI2	78 (64.5%)	43 (35.5%)
intI3	81 (66.9%)	40 (33.1%)
lasI	60 (49.6%)	61 (50.4%)

 Table (3): Frequency of genes involved in colistin resistance in Acinetobacter baumannii isolates. 484